| Ytd | -41.73% | |
| 1y | -48.10% |
| Open | 15.73 | Prev Close | 15.73 | Low | 15.73 | High | 16.15 | Mkt Cap | 4.45B |
| Vol | 11.22K | Avg Vol | 3.01M | EPS | -0.18 | P/E | -86.52 | Forward P/E | 43.29 |
| Beta | N/A | Short Ratio | 4.75 | Inst. Own | 56.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 16.85 | 200-d Avg | 22.28 | 1yr Est | 27.00 |
Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implyin
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio c
This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway m
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithms
ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewi
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it ha
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-c
Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and po
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2
Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-genera
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Comp
A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘
Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corpor
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was cor
ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 year
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, s
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the tim
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved target
Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, produ
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transc
Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting
Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowe
Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and
IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-cen
JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the pr
Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to
Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst
Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company an
Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patien
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro
Jefferies analyst Tycho Peterson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Bu
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperfo
Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid mal
Caris Life Sciences stock surges on positive Achieve 1 cancer test data. See key CAI levels and stud
Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company an
Small caps lagged while emerging markets surged to record highs amid historic Supreme Court's ru
Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings
Stocks That Hit 52-Week Lows On Monday